山东步长制药股份有限公司关于全资子公司再次通过高新技术企业认定的公告

Group 1 - Shandong Buchang Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Baoding Tianhao Pharmaceutical Co., Ltd., has received the "High-tech Enterprise Certificate" from relevant authorities, indicating its strong innovation and R&D capabilities [2] - The certificate is valid for three years, from November 11, 2024, and allows Baoding Tianhao to enjoy a reduced corporate income tax rate of 15% from 2024 to 2026 [2] - This recognition is expected to positively impact Baoding Tianhao's future development strategy and overall sustainable growth [2] Group 2 - The company has initiated a share repurchase program, approved by the board on December 26, 2024, with a maximum repurchase price set at 23 yuan per share [6] - As of April 30, 2025, the company has repurchased a total of 6,620,630 shares, representing 0.60% of its total share capital, with a total expenditure of approximately 98 million yuan [7] - The repurchase aligns with relevant regulations and the company's stated objectives, with ongoing compliance and disclosure obligations [7]